Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

CONCORDBIO's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 6.96800
forwardPE 29.06020
debtToEquity 0.08800
earningsGrowth -0.34100
revenueGrowth -0.20400
grossMargins 0.64202
operatingMargins 0.28374
trailingEps 30.91000
forwardEps 0.00000

With a current ratio of 6.968, CONCORDBIO has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that CONCORDBIO is in a strong position to meet its immediate financial obligations without difficulty.
CONCORDBIO's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
Concord Biotech Limited's low earnings and revenue growth highlight a potential decline in profitability. This suggests that the company's financial health may be weakening, and profits could shrink as a result.
CONCORDBIO's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

The current price of CONCORDBIO, in relation to its projections, presents a neutral outlook. There are no discernible risks or opportunities at this stage, indicating that investors may need to await further developments to make informed decisions regarding their positions in the stock.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


CONCORDBIO has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view CONCORDBIO as a reliable choice for their money, offering a promising avenue for future growth and financial gains.